Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis

Gottesdiener, Keith; Schnitzer, Thomas J.; Fisher, Chester; Bockow, Barry; Markenson, Joseph A.; Ko, A.; DeTora, Lisa; Curtis, Sean; Geissler, Lori; Gertz, Barry J.

doi:10.1093/rheumatology/41.9.1052

Cited by 105 publications

(80 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it is not possible to draw conclusions about the safety of any drug on the basis of a single-dose study. Long-term studies, both in patients with osteoarthritis and rheumatoid arthritis, have demonstrated a good tolerability profile for etoricoxib doses up to 120 mg [14,15].…”

Section: Discussionmentioning

confidence: 99%

Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial

Malmström¹,

Kotey

Cichanowitz³

et al. 2003

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objective: To determine the efficacy of etoricoxib in the treatment of primary dysmenorrhea. Methods: Seventy-three women were randomly assigned to receive single oral doses of etoricoxib 120 mg, placebo, or naproxen sodium 550 mg at the onset of moderate to severe pain associated with menses. During 3 consecutive menstrual cycles in this double-blind, 3-period, crossover study, pain intensity and pain relief were assessed over the 24-hour period following dosing, and global ratings of therapy were made at 8 and 24 h after dosing. Tolerability was assessed by spontaneous reports of adverse experiences. Results: Etoricoxib 120 mg provided analgesic efficacy superior to placebo for the primary endpoint, total pain relief over 8 h (TOPAR8, p < 0.001), and for all secondary endpoints (p < 0.050). The analgesic effect of etoricoxib 120 mg over the first 8 h was similar to that of naproxen sodium 550 mg. All treatments were well tolerated. Conclusions: Etoricoxib 120 mg provided rapid and sustained analgesia that was superior to placebo and similar to that of naproxen sodium 550 mg.

show abstract

Section: Discussionmentioning

confidence: 99%

Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial

Malmström¹,

Kotey

Cichanowitz³

et al. 2003

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Eligible subjects were assessed according to the American College of Rheumatology (ACR) criteria for clinical knee OA (20) with a pain score of $20 mm on a 100-mm visual analog scale (VAS). Subjects also had an ACR function class rating of I, II, and III (21), and relatively good health, with a score of 0-2 on a 5-point Likert scale (where 0 indicates very good health and 4 indicates very poor health), according to the global investigator assessment of disease status (22).…”

Section: Methodsmentioning

confidence: 99%

Cross‐Sectional and Longitudinal Associations Between Serum Levels of High‐Sensitivity C‐Reactive Protein, Knee Bone Marrow Lesions, and Knee Pain in Patients With Knee Osteoarthritis

Zhu

Jin

Wang

et al. 2016

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To describe associations between serum high-sensitivity C-reactive protein (hsCRP), knee bone marrow lesions (BMLs), and knee pain, cross-sectionally and longitudinally, in patients with knee osteoarthritis (OA). Methods. Patients (n 5 192) with symptomatic knee OA (mean age 63 years, range 50-79, women 53%) were assessed at baseline and after 24 months. Serum hsCRP was measured using enzyme-linked immunosorbent assay. Knee BMLs were scored using the modified Whole-Organ Magnetic Resonance Imaging (MRI) Score from T2-weighted fat-supressed fast spin-echo MRI. Knee pain was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index. Results. Quartiles of baseline serum hsCRP were associated with the presence of knee BMLs (prevalence ratio 1.07 per quartile [95% confidence interval (95% CI) 1.00, 1.15]) and total knee pain scores (b 13.66 per quartile [95% CI 2.26, 25.07]) in multivariable analyses. Longitudinally, higher baseline hsCRP was associated with an increase in BML score (risk ratio 1.37 per quartile [95% CI 1.10, 1.70]), and change in hsCRP was positively associated with change in BML score (b 0.19 [95% CI 0.05, 0.34]) in adjusted analyses. Baseline hsCRP was not associated with change in total knee pain, but change in hsCRP was positively and significantly associated with change in total knee pain (b 4.71 [95% CI 0.48, 8.94]). This became nonsignificant after adjustment for changes in BML score. Conclusion. In patients with knee OA, serum hsCRP is associated with knee BML scores and, to a lesser extent, pain both cross-sectionally and longitudinally, suggesting that inflammation is linked with BMLs and their associated pain.

show abstract

“…The COX-2 hypothesis has been validated in animal models of inflammation and in human clinical trials with inhibitors such as celecoxib (McKenna et al, 2002), rofecoxib (Weaver, 2001), valdecoxib (Ormrod et al, 2002), etoricoxib (Gottesdiener et al, 2002), and lumiracoxib (Sorbera et al, 2002), which are selective COX-2 inhibitors. We recently reported a biochemically based strategy for the facile conversion of carboxylic acid-containing NSAIDs such as indomethacin (Kalgutkar et al, 2000a,b;Kozak et al, 2002) and meclofenamic acid (Kalgutkar et al, 2000a(Kalgutkar et al, , 2002 to selective COX-2 inhibitors.…”

mentioning

confidence: 99%

Studies on the Metabolism of the Novel, Selective Cyclooxygenase-2 Inhibitor Indomethacin Phenethylamide in Rat, Mouse, and Human Liver Microsomes: Identification of Active Metabolites

et al. 2004

View full text Add to dashboard Cite

This article is available online at http://dmd.aspetjournals.org ABSTRACT:The metabolism of 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-N-phenethyl-acetamide (indomethacin phenethylamide, LM-4108), a highly selective cyclooxygenase-2 inhibitor, was studied in rat, mouse, and human liver microsomes. The primary site of oxidation in all species examined was on the methylene carbons of the phenethyl side chain to form the 1-and 2-hydroxy and 2-oxo metabolites as determined by electrospray ionization liquid chromatography-tandem mass spectrometry. Half-lives for the disappearance of 10 M LM-4108 in rat, human, and mouse liver microsomes (0.15 pmol P450/ml) were 11 min, 21 min, and 51 min, respectively. Indomethacin formation was not observed in incubations with rat, mouse, or human liver microsomes. Both the 2-hydroxy-LM-4108 and 2-oxo-LM-4108 metabolites were synthesized and found to be equipotent to the parent compound with regard to COX-2 inhibitory potency and selectivity

show abstract

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis

Abstract: Etoricoxib 60 mg once daily showed maximal efficacy in treating OA in this study. Etoricoxib 5-90 mg once daily was generally well tolerated in OA patients for up to 14 weeks.

Cited by 105 publications

References 14 publications

Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial

Analgesic Efficacy of Etoricoxib in Primary Dysmenorrhea: Results of a Randomized, Controlled Trial

Cross‐Sectional and Longitudinal Associations Between Serum Levels of High‐Sensitivity C‐Reactive Protein, Knee Bone Marrow Lesions, and Knee Pain in Patients With Knee Osteoarthritis

Studies on the Metabolism of the Novel, Selective Cyclooxygenase-2 Inhibitor Indomethacin Phenethylamide in Rat, Mouse, and Human Liver Microsomes: Identification of Active Metabolites

Contact Info

Product

Resources

About